mena-header

MIDDLE EAST & NORTH AFRICA

We supply globally branded pharmaceutical products as well as local brands into multiple territories within Middle East and North Africa (“MENA”). Egypt, Algeria and Saudi Arabia combined contributed approximately 50% to total sales in MENA for the 2019 financial year.

Key Countries

Algeria,
Egypt,
Morocco,
Saudi Arabia,
United Arab Emirates

Contribution to Group revenue

pic-20europe

Revenue contribution - by therapeutic category

pic-19europe
  • In the US, growth in total medicine spending net of rebates, discounts and other price concessions increased 4,5% to USD344 billion
  • The volume of the United States prescription pharmaceutical market grew 2,7% in 2018

Source: IQVIA Market Prognosis

STATISTICS

Number of products launched:

7

(2018: 5)#

In-market sales value of pipeline as at 30 June 2019 anticipated to be launched in:

0 – 2 years

USD107 million

3 – 5 years

USD145 million

Number of product recalls:

Nil

(2018: Nil)

Average staff turnover:

19,2%

(2018: 10,9%)

Number of work-related fatalities:

Nil

(2018: Nil)

Number of permanent employees:

june-09

# The number of product launches has been restated to take into account discontinued operations.


Revenue
2019
R'million
2018 (CER)
R'million
change
%
Total 1 0561702
Regional Brands7016518
Sterile Focus Brands355381(7)
Anaesthetics Brands23721112
Thrombosis Brands118170(31)

Note: Commercial Pharmaceuticals revenue is disclosed by customer geography.